Blood Res.  2014 Sep;49(3):144-145. 10.5045/br.2014.49.3.144.

Management of hemophilia in Korea: the past, present, and future

  • 1Hemophilia Working Party, Korean Society of Hematology, Department of Pediatrics, Daegu Catholic University School of Medicine, Daegu, Korea.


No abstract available.

MeSH Terms

Hemophilia A*

Cited by  2 articles

Safety and effectiveness of Rixubis in patients with hemophilia B: a real-world, prospective, postmarketing surveillance study in South Korea
Eun Jin Choi, Tai ju Hwang, Yong Mook Choi, Hugh Chul Kim, Myung Chul Yoo, Haylee Song, Kayode Badejo
Blood Res. 2020;55(4):246-252.    doi: 10.5045/br.2020.2020225.

Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients
Chur Woo You, Hee Jo Baek, Sang Kyu Park, Young Shil Park, Ho-Jin Shin, Werner Engl, Srilatha Tangada
Blood Res. 2019;54(3):198-203.    doi: 10.5045/br.2019.54.3.198.


1. Yoo KY, Kim SK, Kwon SS, et al. Life expectancy of Korean haemophiliacs, 1991-2012. Haemophilia. 2014; 20:e356–e358. PMID: 24948408.
2. Berntorp E, Boulyjenkov V, Brettler D, et al. Modern treatment of haemophilia. Bull World Health Organ. 1995; 73:691–701. PMID: 8846496.
3. Oldenburg J, Austin SK, Kessler CM. ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective. Haemophilia. 2014; 20(Suppl 6):17–26. PMID: 24975701.
4. Hwang TJ. Annual report of Korea Hemophilia Foundation 2012. Seoul, Korea: Korea Hemophilia Foundation;2012. p. 16–22.
5. Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood. 2012; 119:3031–3037. PMID: 22223821.
6. Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013; 369:2313–2323. PMID: 24304002.
7. Peyvandi F, Garagiola I, Seregni S. Future of coagulation factor replacement therapy. J Thromb Haemost. 2013; 11(Suppl 1):84–98. PMID: 23809113.
8. Carcao M. Changing paradigm of prophylaxis with longer acting factor concentrates. Haemophilia. 2014; 20(Suppl 4):99–105. PMID: 24762284.
9. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl. 1965; 77:3–132. PMID: 5854304.
10. Collins PW, Fischer K, Morfini M, Blanchette VS, Bjorkman S. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia. 2011; 17:2–10. PMID: 20731726.
11. Collins PW. Personalized prophylaxis. Haemophilia. 2012; 18(Suppl 4):131–135. PMID: 22726096.
12. Yoo KY, Choi YM, Hwang TJ, Choi EJ. The efficacy of prophylaxis for children with severe hemophilia in Korea-An experience of single institute. Clin Pediatr Hematol Oncol. 2012; 19:79–85.
13. Gringeri A, Ewenstein B, Reininger A. The burden of bleeding in haemophilia: is one bleed too many? Haemophilia. 2014; 20:459–463. PMID: 24472015.
14. Bolton-Maggs PH. Optimal haemophilia care versus the reality. Br J Haematol. 2006; 132:671–682. PMID: 16487168.
Full Text Links
  • BR
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: